Long-Term Outcomes of Combined Phacoemulsification and Non-Penetrating Deep Sclerectomy versus Standalone Non-Penetrating Deep Sclerectomy Authors: Khaled Safadi, Gustavo Adolfo Gutierrez Vargas, Yaacov Cnaany, Shoham Kubovsky, Wiessam Abu Ahmad, Gabriel Greifner Published: 2026 ABSTRACT PurposeTo compare the efficacy and safety of combined phacoemulsification and non-penetrating deep sclerectomy (Phaco-NPDS) with standalone NPDS in a large glaucoma cohort with long-term follow-up.MethodsThis retrospective cohort study included eyes that underwent primary NPDS with or without phacoemulsification between 2013 and 2018, with follow-up through 2023. Eyes were grouped as Phaco-NPDS, NPDS-IOL, or NPDS-Phakic. Procedure selection reflected clinical decision-making (primarily lens status/cataract, age, and visual acuity). The primary outcome was surgical success. Success was defined as postoperative IOP 5–21 mmHg with a ≥20% reduction from baseline at each follow-up. Complete success required no hypotensive medications, whereas qualified success was defined with or without hypotensive medications. Success was also assessed using stricter IOP upper limits (≤18, ≤15, and ≤12 mmHg). Secondary outcomes included visual acuity (VA), IOP, medication use, postoperative procedures, and complications.ResultsA total of 276 eyes from 242 patients were included (mean age 71.7±14.9 years; follow-up 4.25±2.4 years). Qualified and complete success rates (IOP 5–21 mmHg) were 78.1% and 69.2% in Phaco-NPDS, 79.0% and 68.0% in NPDS-IOL, and 83.4% and 73.3% in NPDS-Phakic, with no significant between-group differences (qualified p=0.46; complete p=0.16). Cox regression showed better complete, but not qualified, success in young phakic eyes without cataract undergoing standalone NPDS compared with Phaco-NPDS. Postoperative mean VA, IOP, and medication use were similar across groups. GPT and needling were more common during the first postoperative year, particularly in the NPDS-IOL group (OR=1.55 and 1.70, respectively). Post-GPT iris incarceration was the most frequent complication (10.5%).ConclusionCombining phacoemulsification with NPDS was not associated with reduced surgical success. Phaco-NPDS should be considered for patients with coexisting cataract and uncontrolled glaucoma when surgical intervention is indicated. In young phakic eyes without cataract, standalone NPDS may be considered to achieve higher complete success at stricter IOP targets. Introduction Glaucoma is the leading cause of irreversible blindness worldwide.1,2 Available treatment options are incapable of reversing pre-existing glaucomatous damage. However, early diagnosis and proper management can impede its progression. As a chronic disease, glaucoma requires lifelong surveillance.3 Intra-ocular pressure (IOP) is the main modifiable risk factor. Maintaining low IOP and reducing diurnal IOP fluctuations (IOP spikes) have been shown to mitigate the progression of visual field loss.4–7 Glaucoma treatment options to lower IOP include medical therapy, laser procedures, and glaucoma filtration surgeries.8 When medical and laser treatments are insufficient to control IOP and halt glaucoma progression, filtration surgery becomes indispensable.7,9,10 Trabeculectomy (Trab) is the traditional and leading glaucoma filtration surgery.11 Non-Penetrating Glaucoma Surgery (NPGS), such as Deep Sclerectomy (NPDS), emerged in the 1990s as an alternative to Trab, offering fewer complications and an improved safety profile.12–14 The main difference between NPDS and Trab is that NPDS involves the creation of a Trabeculo-Descemet’s Membrane (TDM) rather than a sclerostomy. TDM preservation has reduced postoperative complications, particularly sudden hypotony, by facilitating gradual and progressive filtration of aqueous humor from the anterior chamber to the subconjunctival space through the membrane.15 Many patients with glaucoma develop visually significant cataracts with advancing age. These two commonly comorbid conditions may be clinically significant and require surgical intervention.16 Different surgical approaches can be followed to address both conditions in the same eye, including treating either the cataract or glaucoma initially, or performing a combined surgery for both.17 The decision depends on several individual patient factors, including visual acuity, glaucoma severity, target IOP, age, and prognosis.18 Several studies have investigated phacoemulsification combined with trabeculectomy (Phaco-Trab), which has become a widely used approach for glaucoma control and concurrent cataract treatment in the same eye.19–21 This trend has led to the integration of phacoemulsification with NPDS (Phaco-NPDS). However, the non-existence of sizable cohorts with extended follow-up and the lack of clinically relevant subgrouping in contemporary studies represent significant evidence gaps in comparisons of Phaco-NPDS and standalone NPDS. Only a few studies have directly compared Phaco-NPDS with standalone NPDS, and these have been limited by small sample sizes or short follow-up periods.22 In addition, postoperative outcomes after glaucoma surgery may evolve over time, emphasizing the importance of durability assessment. The Primary Tube Versus Trabeculectomy Study reported similar failure rates between procedures at 3 years, with lower IOP and fewer medications after trabeculectomy, highlighting the value of extended follow-up when comparing surgical techniques.9 Therefore, we aimed to compare the efficacy and safety of Phaco-NPDS and standalone NPDS in a large cohort with long-term follow-up. Materials and Methods This retrospective case series was conducted in accordance with the tenets of the Declaration of Helsinki and was approved by the Institutional Ethics Committee of Hadassah University Medical Center. The study included eyes that underwent primary NPDS surgery (either combined with or without phacoemulsification) between 2013 and 2018, with follow-up until 2023, at Hadassah University Medical Center in Jerusalem, Israel. Procedure selection was based on routine clinical decision-making by the treating surgeon, considering lens status, cataract presence and severity and its impact on visual acuity, patient age, and glaucoma characteristics. Eyes with less than 3 months of follow-up, eyes that underwent NPDS as a second filtration surgery and eyes that had angle closure glaucoma were excluded. All surgeries were performed by a single surgeon, G.G. As this was a retrospective study, we obtained a waiver of informed consent from the institutional ethics committee of the Hadassah-Hebrew University Medical Center. There is no publication of identifiable information, such as images or case details. The collected data included age, gender, ocular history, diagnosis, type of surgery, lens status, highest measured IOP (T-max) at presentation, central corneal thickness (CCT), medication use, mean deviation from the Humphrey Visual Field Analyzer 24–2 program, visual acuity (VA), and IOP before and after surgery throughout the available follow-up period for each patient. Additionally, data on YAG laser Goniopuncture (GPT) procedures, Needling procedures, additional surgeries, and complications were recorded. All VA values were converted to LogMAR. To obtain numerical values for low VA, the following conversions were made: light perception (LP) = 4 (Snellen equivalent 0.0001), hand movement (HM) = 3 (Snellen equivalent 0.001), finger counting (FC) = 2 (Snellen equivalent 0.01).23 The eyes were divided into three groups: Phaco-NPDS, NPDS-Phakic, and NPDS-IOL. The Phaco-NPDS group included eyes that underwent combined phacoemulsification and NPDS. The NPDS-Phakic group included phakic eyes that underwent NPDS alone, while the NPDS-IOL group included pseudophakic eyes that underwent NPDS alone. Given the retrospective study design, postoperative management and follow-up intervals were not standardized, introducing heterogeneity that reflects real-world clinical practice. The primary outcome measure was surgical success rates. Secondary outcome measures included VA, IOP, medication use, postoperative procedures, and complications. Phaco-NPDS Surgical Technique After the formation of a fornix-based conjunctival flap in the upper quadrant, a 5×5 mm half-scleral thickness, rectangular-shaped superficial scleral flap was dissected up to 1 mm into the clear cornea. Mitomycin C (MMC) 0.02% antimetabolite was then soaked into three small sponge pieces and placed underneath the conjunctival flap for 2 minutes. Afterward, the sponges were removed, and the area was thoroughly washed with sterile Balanced Salt Solution (BSS). In the next stage, phacoemulsification surgery was performed. A 2.4 mm clear corneal incision from the temporal quadrant, and two side-port incisions were made approximately at the 3 and 9 o’clock corneal positions. Following continuous curvilinear capsulorhexis, hydrodissection, and hydrodelineation, the nucleus was emulsified using the horizontal chopping technique. Cortical remnants were removed by aspiration and irrigation. An intra-ocular lens (IOL) was implanted inside the capsular bag. Viscoelastic material in the anterior chamber was aspirated, and the side ports were closed with stromal hydration. Resuming NPDS surgery, a second 3×4 mm rectangular-shaped deep scleral flap was constructed, leaving a thin layer of deep sclera over the underlying uvea. The dissection continued into Schlemm’s canal to open its external wall, then anteriorly into the clear cornea to create a wide TDM window. Afterward, the deep flap was excised and the internal wall of Schlemm’s canal was peeled off. At this stage, percolation of aqueous humour was observed from the anterior chamber along the TDM surface. The superficial scleral flap was repositioned and anchored to the sclera using two 9–0 Vicryl sutures. Healaflow,24 a cross-linked sodium hyaluronate viscoelastic implant used as a space-maintaining adjunct in filtering surgery, was injected underneath the scleral flap into the subscleral lake as a spacer. The conjunctiva was closed with 9–0 Vicryl sutures, and the absence of leakage was ensured. Intracameral and subconjunctival antibiotics were administered, and the surgery was terminated. Solo NPDS was performed as previously described, but without phacoemulsification surgery. Definition of Success Definitions of success and failure were chosen in accordance with the World Glaucoma Association consensus guidelines.25 Success was achieved if the postoperative IOP ranged between 5–21 mmHg and ≥20% reduction in IOP at each follow-up visit when compared with baseline value. Complete success was achieved when the success rate analysis included only eyes without hypotensive medications. Qualified success was achieved when the success rate analysis included eyes with and without hypotensive medications postoperatively. Qualified and complete success rates were additionally analyzed for different IOP upper limits including ≤18 mmHg, ≤15 mmHg, and ≤12 mmHg. For all these thresholds, success also required a ≥20% reduction in IOP at each follow-up visit compared to baseline. Failure was defined as IOP above 21 mmHg, below 5 mmHg, or ≤20% reduction in IOP at each follow-up visit when compared with baseline value, at no fewer than two consecutive follow-up visits, or if any of the following occurred: loss of light perception, bleb revision surgery, or additional glaucoma filtration surgery. Postoperative Nd:YAG goniopuncture (GPT) and needling procedures were considered adjunctive postoperative interventions and were recorded and analyzed separately; they were not classified as primary surgical failure unless a formal repeat glaucoma filtering surgery or bleb revision was required. Statistical Analysis Data was recorded in Microsoft Excel and analyzed using GraphPad Prism 8 (GraphPad Software, CA, USA). Measurements of continuous variables are summarized as means, standard deviations (SD), 25% percentile, medians, and 75% percentile. Categorical variables are presented as frequencies and percentages. For the statistical significance testing of the interval scale parameters across the three groups, a one-way ANOVA test was used. For statistical analysis of VA and IOP, a one-way ANOVA non-parametric Kruskal–Wallis test was conducted. Fisher’s exact and chi-square tests were used to analyze the categorical parameters. Further evaluations were performed using a single-variable odds ratio analysis. Kaplan-Meier survival curves were plotted for each group according to four different target IOP ranges: 5–21mmHg, 5–18mmHg, 5–15mmHg, and 5–12mmHg. The Log-rank (Mantel-Cox) test was performed to assess surgical success rates based on four IOP thresholds (≤21 mmHg, ≤18 mmHg, ≤15 mmHg, and ≤12 mmHg). In addition, Cox proportional hazards regression models were used to assess surgical success rates based on four IOP thresholds (≤21 mmHg, ≤18 mmHg, ≤15 mmHg, and ≤12 mmHg). Separate models were fit for each threshold and both definitions of success (qualified and complete success). The predictor variables included surgery groups, gender, age, and diagnosis. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated to estimate the effect of these predictors on surgical success. Nagelkerke’s R-squared was reported to evaluate the goodness-of-fit for each model. Analyses were conducted in R statistical software version 3.5.0 (R Project for Statistical Computing). Two-sided P-values less than 0.05 were considered statistically significant for all models. No formal sample size calculation was performed, as this retrospective cohort included all eligible cases during the study period. The NPDS-Phakic subgroup was comparatively small, and subgroup analyses (including Cox regression estimates) should be interpreted carefully. Results A total of 276 eyes from 242 patients were included in the study (Table 1). There was no significant difference in gender distribution among the three groups (p=0.59). The mean age of the patients at presentation was 71.7±14.9 years. The NPDS-Phakic group was the youngest (NPDS-Phakic vs. Phaco-NPDS p<0.0001, NPDS-Phakic vs. NPDS-IOL p<0.0001). The NPDS-IOL group was the oldest and there was no significant difference in the mean age between the Phaco-NPDS and NPDS-IOL groups (p=0.14). The mean follow-up period was 4.25±2.4 years. The most common diagnosis was Pseudoexfoliative glaucoma (PXFG, 46.74%) (Table 1). There was a significant difference in the prevalence of PXFG between the three groups (p=0.019). In subgroup analysis, there was no significant difference in the prevalence of PXFG between the Phaco-NPDS and NPDS-IOL groups (p=0.5), but the prevalence was significantly lower in the NPDS-Phakic group compared to both the Phaco-NPDS and NPDS-IOL groups (p=0.005 and p=0.02, respectively). This distribution is consistent with PXF being an age-related condition that is more prevalent in older patients,26 as reflected in the Phaco-NPDS and NPDS-IOL groups. The second most common diagnosis was primary open-angle glaucoma (POAG, 39.5%). There was no significant difference in the prevalence of POAG, secondary glaucoma, or normal-tension glaucoma (NTG) between the three groups (p=0.98, p=0.18, and p=0.91, respectively). There was a significant difference in the prevalence of juvenile open-angle glaucoma (JOAG) among the three groups (p<0.0001). It was significantly more prevalent in the NPDS-Phakic group compared to both the Phaco-NPDS (p=0.0003) and NPDS-IOL (p=0.0002) groups. This distribution is consistent with the younger age profile of this subgroup.Table 1Baseline Demographics and CharacteristicsGroupPhaco-NPDS(n = 146)NPDS-IOL(n = 100)NPDS-Phakic(n = 30)All(n = 276)P-valueGender(% in Group)MF87 (59.6%)59 (40.4%)60 (60%)40 (40%)15 (50%)15 (50%)162 (58.7%)114 (41.3%)0.59bMeana Age (Years)73.43±10.74(68, 74, 80)76.7±11.02(69.25, 79, 84.5)49.31±20.39(34.5, 52, 64.2)71.69±14.9(66, 74.5, 81)<0.0001cDiagnosis(Number, %)PXFG75/146 (51.37%)47/100 (47%)7/30 (23.33%)129/276 (46.74%)0.019cPOAG57/146 (39.04%)40/100 (40%)12/30 (40%)109/276 (39.5%)0.98cSecondary G7/146 (4.8%)8/100 (8%)4/30 (13.33%)19/276 (6.88%)0.18cNTG6/146 (4.11%)5/100 (5%)1/30 (3.34%)12/276 (4.34%)0.91cJOAG1/146 (0.68%)0/100 (0%)6/30 (20%)7/276 (2.54%)<0.0001cNotes: aMean ±SD (25% percentile, Median, 75% percentile). bChi-square test. cOne-way ANOVA test.Abbreviations: PXFG, Pseudoexfoliative Glaucoma; POAG, Primary Open Angle Glaucoma; Secondary Glaucoma, Uveitic Glaucoma, Steroids Induced Glaucoma, Trauma and Tumors. NTG, Normal Tension Glaucoma; JOAG. Juvenile Open-Angle Glaucoma (JOAG). Table 1Baseline Demographics and CharacteristicsGroupPhaco-NPDS(n = 146)NPDS-IOL(n = 100)NPDS-Phakic(n = 30)All(n = 276)P-valueGender(% in Group)MF87 (59.6%)59 (40.4%)60 (60%)40 (40%)15 (50%)15 (50%)162 (58.7%)114 (41.3%)0.59bMeana Age (Years)73.43±10.74(68, 74, 80)76.7±11.02(69.25, 79, 84.5)49.31±20.39(34.5, 52, 64.2)71.69±14.9(66, 74.5, 81)<0.0001cDiagnosis(Number, %)PXFG75/146 (51.37%)47/100 (47%)7/30 (23.33%)129/276 (46.74%)0.019cPOAG57/146 (39.04%)40/100 (40%)12/30 (40%)109/276 (39.5%)0.98cSecondary G7/146 (4.8%)8/100 (8%)4/30 (13.33%)19/276 (6.88%)0.18cNTG6/146 (4.11%)5/100 (5%)1/30 (3.34%)12/276 (4.34%)0.91cJOAG1/146 (0.68%)0/100 (0%)6/30 (20%)7/276 (2.54%)<0.0001cNotes: aMean ±SD (25% percentile, Median, 75% percentile). bChi-square test. cOne-way ANOVA test.Abbreviations: PXFG, Pseudoexfoliative Glaucoma; POAG, Primary Open Angle Glaucoma; Secondary Glaucoma, Uveitic Glaucoma, Steroids Induced Glaucoma, Trauma and Tumors. NTG, Normal Tension Glaucoma; JOAG. Juvenile Open-Angle Glaucoma (JOAG). Baseline Demographics and Characteristics Notes: aMean ±SD (25% percentile, Median, 75% percentile). bChi-square test. cOne-way ANOVA test. Abbreviations: PXFG, Pseudoexfoliative Glaucoma; POAG, Primary Open Angle Glaucoma; Secondary Glaucoma, Uveitic Glaucoma, Steroids Induced Glaucoma, Trauma and Tumors. NTG, Normal Tension Glaucoma; JOAG. Juvenile Open-Angle Glaucoma (JOAG). At presentation, a total of 176 eyes were phakic (63.8%) and 100 eyes were pseudophakic (36.2%). Of the phakic eyes, 83% underwent combined Phaco-NPDS surgery (Phaco-NPDS group), and 17% underwent solo NPDS (NPDS-Phakic group). Postoperatively, 36.7% of the eyes in the NPDS-Phakic group underwent cataract surgery after a mean of 3.4±2.3 years. Of these, one eye underwent cataract surgery combined with bleb revision surgery due to uncontrolled IOP two years after primary NPDS surgery. In the remaining eyes, glaucoma continued to be under control. Perforation of the Trabeculo-Descemet’s Membrane (TDM) during NPDS surgery occurred in 31 out of 276 eyes (11.23%). Among those eyes, 45.2% were in the Phaco-NPDS group, 35.5% in the NPDS-Phakic group, and 19.35% in the NPDS-IOL group. A statistically significant association was found between TDM perforation and surgery type (χ2=22.6, p <0.0001). The odds ratio for perforation was higher in the NPDS-Phakic group than in the Phaco-NPDS and NPDS-IOL groups (OR=5.45, 1, and 0.6, respectively). Visual Acuity (VA, LogMAR) Preoperatively, the mean visual acuity (LogMAR) was 0.41±0.53 in the Phaco-NPDS group, 0.42±0.58 in the NPDS-IOL group, and 0.27±0.56 in the NPDS-Phakic group. There was no significant difference between the Phaco-NPDS and NPDS-IOL groups (p=0.47). However, the preoperative visual acuity of the NPDS-Phakic group was significantly better than that of the Phaco-NPDS (p=0.001) and NPDS-IOL (p=0.03) groups. Postoperatively, the mean visual acuity (LogMAR) was 0.46±0.65 in the Phaco-NPDS group, 0.54±0.61 in the NPDS-IOL group, and 0.38±0.6 in the NPDS-Phakic group. There was no significant difference between the Phaco-NPDS and NPDS-IOL groups (p=0.08), with a trend that did not reach statistical significance, or between the Phaco-NPDS and NPDS-Phakic groups (p=0.8). Likewise, there was no significant difference between the NPDS-IOL and NPDS-Phakic groups (p=0.06), with a trend that did not reach statistical significance. Intra-Ocular Pressure (IOP, mmHg) Preoperatively, the mean IOP was significantly higher in the NPDS-IOL group than in the Phaco-NPDS group (p=0.002, Table 2). There was no significant difference between the Phaco-NPDS and NPDS-Phakic groups (p=0.25), nor between the NPDS-IOL and NPDS-Phakic groups (p>0.9). Postoperatively, the mean IOPs significantly decreased in all groups compared to the baseline (p<0.0001, Table 2, Figure 1). There was no significant difference in the mean IOP of each group in comparison with the other groups after 1, 3 and 5 years (Table 2). The IOPs at 1, 3, and 5 years after surgery, in relation to the IOP at baseline in each group (Figure 2), were predominantly below the no-change line, and most of them were below the 20% reduction line.Table 2Clinical Outcomes of Intraocular Pressure (IOP) and IOP-Lowering Medications at Baseline, 1, 3, and 5 Years After SurgeryOutcome (Meana)Phaco-NPDSNPDS-IOLNPDS-PhakicAllIOP (mmHg)Baseline23.97±8.43(17.5, 23, 28)27.42±8.28(21, 25, 34)25.87±7.04(21.7, 26, 28.5)25.43±8.36(19, 24, 30)1 Year11.9±3.87(10, 12, 14)10.9±4.18(8, 10, 14)12.26±4.2(9, 12, 14)11.59±4.04(9, 11, 14)3 Years10.77±4.2(7.5, 11, 14)10.19±4.53(7, 10, 12.5)12.5±3.84(9.5, 12, 15)10.76±4.31(8, 11, 13)5 Years10.65±4.33(7, 10, 13)9.02±4.3(6, 8.5, 11)12.69±4.16(9.5, 13, 15)10.42±4.42(7, 10, 13)P-valuebBaseline 0.002 ⱡ, 0.25 #, >0.9 §1 Year 0.21 ⱡ, >0.9 #, 0.7 §3 Years 0.81 ⱡ, 0.41 #, 0.1 §5 Years 0.39 ⱡ, 0.19 #, 0.01 §MedicationsBaseline3.41±0.92(3, 4, 4)3.81±0.93(3, 4, 4)3.7±0.91(3, 4, 4)3.58±0.94(3, 4, 4)1 Year0.1±0.55(0, 0, 0)0.13±0.52(0, 0, 0)0.22±0.7(0, 0, 0)0.12±0.56(0, 0, 0)3 Years0.17±0.54(0, 0, 0)0.36±0.92(0, 0, 0)0.33±0.68(0, 0, 0.25)0.3±0.79(0, 0, 0)5 Years0.24±0.69(0, 0, 0)0.44±1.02(0, 0, 0)0.5±1.1(0, 0, 0.25)0.34±0.87(0, 0, 0)P-valuebBaseline 0.01 ⱡ, 0.6 #, >0.9 §1 Year >0.9 ⱡ, 0.56 #, >0.9 §3 Years 0.78 ⱡ, 0.59 #, >0.9 §5 Years >0.9 ⱡ, 0.78 #, >0.9 §Notes: aMean ±SD (25% percentile, Median, 75% Percentile). bKruskal–Wallis test with post hoc analysis using Dunn’s multiple comparisons test. ⱡPhaco-NPDS vs. NPDS-IOL. #Phaco-NPDS vs. NPDS-Phakic. §NPDS-IOL vs NPDS-Phakic. Figure 1The graph shows the mean intraocular pressure (IOP, mmHg) before and after surgery across the follow-up period for each group. Red, blue, and green lines represent the Phaco-NPDS, NPDS-IOL, and NPDS-Phakic groups, respectively.A line graph showing the mean intraocular pressure, measured in millimeters of mercury, over time from pre-operation to 8 years post-operation. The x-axis is labeled with time intervals: Pre-Op, 1 week, 1 month, 3 months, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years and 8 years. The y-axis is labeled as IOP in millimeters of mercury, ranging from 0 to 40. Three curves are plotted, each representing different groups. Initially, the mean intraocular pressure is high at pre-operation, then significantly decreases at 1 week post-operation. Over the follow-up period, the mean intraocular pressure remains relatively stable across all groups, with slight variations observed at different intervals. The graph visually represents the long-term effects of surgery on intraocular pressure across multiple years.Line graph showing mean intraocular pressure over time from pre-operation to 8 years post-operation. Figure 2The graphs represent the mean intraocular pressure (IOP) at 1 year, 3 years and 5 years after surgery, in relation to the mean IOP at baseline.Image A: Scatter plot of intraocular pressure (IOP) 1 year post-surgery vs. baseline. X-axis: 'IOP (mmHg) - Baseline'; Y-axis: 'IOP (mmHg) - 1 Year'. Data points: Phaco-NPDS, NPDS-IOL, NPDS-Phakic groups. Includes no change line, 20% reduction line, 21 mmHg and 5 mmHg lines. Image B: Scatter plot of IOP 3 years post-surgery vs. baseline. X-axis: 'IOP (mmHg) - Baseline'; Y-axis: 'IOP (mmHg) - 3 Years'. Same groups and reference lines as Image A. Image C: Scatter plot of IOP 5 years post-surgery vs. baseline. X-axis: 'IOP (mmHg) - Baseline'; Y-axis: 'IOP (mmHg) - 5 Years'. Consistent data points and reference lines with previous plots.Three scatter plots showing intraocular pressure changes at 1, 3 and 5 years post-surgery compared to baseline. Table 2Clinical Outcomes of Intraocular Pressure (IOP) and IOP-Lowering Medications at Baseline, 1, 3, and 5 Years After SurgeryOutcome (Meana)Phaco-NPDSNPDS-IOLNPDS-PhakicAllIOP (mmHg)Baseline23.97±8.43(17.5, 23, 28)27.42±8.28(21, 25, 34)25.87±7.04(21.7, 26, 28.5)25.43±8.36(19, 24, 30)1 Year11.9±3.87(10, 12, 14)10.9±4.18(8, 10, 14)12.26±4.2(9, 12, 14)11.59±4.04(9, 11, 14)3 Years10.77±4.2(7.5, 11, 14)10.19±4.53(7, 10, 12.5)12.5±3.84(9.5, 12, 15)10.76±4.31(8, 11, 13)5 Years10.65±4.33(7, 10, 13)9.02±4.3(6, 8.5, 11)12.69±4.16(9.5, 13, 15)10.42±4.42(7, 10, 13)P-valuebBaseline 0.002 ⱡ, 0.25 #, >0.9 §1 Year 0.21 ⱡ, >0.9 #, 0.7 §3 Years 0.81 ⱡ, 0.41 #, 0.1 §5 Years 0.39 ⱡ, 0.19 #, 0.01 §MedicationsBaseline3.41±0.92(3, 4, 4)3.81±0.93(3, 4, 4)3.7±0.91(3, 4, 4)3.58±0.94(3, 4, 4)1 Year0.1±0.55(0, 0, 0)0.13±0.52(0, 0, 0)0.22±0.7(0, 0, 0)0.12±0.56(0, 0, 0)3 Years0.17±0.54(0, 0, 0)0.36±0.92(0, 0, 0)0.33±0.68(0, 0, 0.25)0.3±0.79(0, 0, 0)5 Years0.24±0.69(0, 0, 0)0.44±1.02(0, 0, 0)0.5±1.1(0, 0, 0.25)0.34±0.87(0, 0, 0)P-valuebBaseline 0.01 ⱡ, 0.6 #, >0.9 §1 Year >0.9 ⱡ, 0.56 #, >0.9 §3 Years 0.78 ⱡ, 0.59 #, >0.9 §5 Years >0.9 ⱡ, 0.78 #, >0.9 §Notes: aMean ±SD (25% percentile, Median, 75% Percentile). bKruskal–Wallis test with post hoc analysis using Dunn’s multiple comparisons test. ⱡPhaco-NPDS vs. NPDS-IOL. #Phaco-NPDS vs. NPDS-Phakic. §NPDS-IOL vs NPDS-Phakic. Clinical Outcomes of Intraocular Pressure (IOP) and IOP-Lowering Medications at Baseline, 1, 3, and 5 Years After Surgery Notes: aMean ±SD (25% percentile, Median, 75% Percentile). bKruskal–Wallis test with post hoc analysis using Dunn’s multiple comparisons test. ⱡPhaco-NPDS vs. NPDS-IOL. #Phaco-NPDS vs. NPDS-Phakic. §NPDS-IOL vs NPDS-Phakic. The graph shows the mean intraocular pressure (IOP, mmHg) before and after surgery across the follow-up period for each group. Red, blue, and green lines represent the Phaco-NPDS, NPDS-IOL, and NPDS-Phakic groups, respectively. The graphs represent the mean intraocular pressure (IOP) at 1 year, 3 years and 5 years after surgery, in relation to the mean IOP at baseline. IOP-Lowering Medications Preoperatively, the mean number of IOP-Lowering medications was significantly higher in the NPDS-IOL group than in the Phaco-NPDS group (p=0.01, Table 2). There was no significant difference between the Phaco-NPDS and NPDS-Phakic groups (p=0.6), nor between the NPDS-IOL and NPDS-Phakic groups (p>0.9). Postoperatively, the mean number of IOP-Lowering medications significantly decreased in all groups compared to the baseline (p<0.0001, Table 2, Figure 3). There was no significant difference in the mean IOP-Lowering medications of each group in comparison with the other groups after 1, 3 and 5 years (Table 2). Figure 3The graph shows the mean number of medications that were used before and after surgery during the follow-up period for each group. Red, blue, and green lines represent the Phaco-NPDS, NPDS-IOL, and NPDS-Phakic groups, respectively.A line graph showing the mean number of medications used over time, from pre-operative to 8 years post-operation. The x-axis is labeled with time intervals: Pre-Op, 1 week, 1 month, 3 months, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years and 8 years. The y-axis is labeled 'Medications' with values ranging from negative 1 to 5. Three lines represent different groups, each showing a significant drop in medication use from pre-op to 1 week, followed by a stable trend with slight variations up to 8 years. Error bars indicate variability at each time point.Line graph showing medication use over time from pre-op to 8 years. The graph shows the mean number of medications that were used before and after surgery during the follow-up period for each group. Red, blue, and green lines represent the Phaco-NPDS, NPDS-IOL, and NPDS-Phakic groups, respectively. YAG Laser Goniopuncture (GPT) Procedures Of the 245 eyes with closed TDM after NPDS surgery, 200 (81.63%) underwent YAG Laser Goniopuncture (GPT) procedure to lower the IOP (Table 3). There was no significant difference in the prevalence of GPT between the three groups (p=0.16). The odds ratio for GPT was higher in the NPDS-IOL group compared to the Phaco-NPDS and NPDS-Phakic groups (OR=1.55, 1, and 0.28, respectively). The mean interval between NPDS surgery and the GPT procedure was 10.94±16.12 months, with no significant difference in comparison between the three groups (p=0.11). The mean IOP decreased significantly after GPT procedures in all groups (Phaco-NPDS p<0.0001, NPDS-IOL p<0.0001, and NPDS-Phakic p=0.0002). The mean delta IOP was significantly higher in the NPDS-IOL group than in the Phaco-NPDS group (p<0.0001), but no significant difference was found between the Phaco-NPDS and NPDS-Phakic groups (p>0.9) or the NPDS-IOL and NPDS-Phakic groups (p>0.9).Table 3GPT and Needling ProceduresProceduresPhaco-NPDSNPDS-IOLNPDS-PhakicAllP-valueNumber of eyes(%)GPT106/132(80.3%)81/94(86.17%)13/19(68.42%)200/245(81.63%)0.16bNeedling25/146(17.12%)26/100(26%)6/30(20%)57/276(21%)0.82bMeana period from NPDS to procedure (Months)GPT13.38±17.2(1.1, 6.7, 19)7.2±11.72(1, 3, 7.9)14.26±25.43(2.2, 4, 10.1)10.94±16.12(1.1, 3.9, 12.5)0.11cNeedling5.76±9.45(1, 2, 6.6)7.78±9.92(1.8, 4.1, 9.2)5.2±5.56(1.5, 3.5, 7.9)6.65±9.27(1.2, 3.1, 7.3)0.59cMeana Delta IOP (mmHg)GPT7.93±5.67(5, 6, 10)12.88±8.6(7, 10, 18)9.4±5.17(5, 10, 13.5)10.02±7.4(5, 8, 13)<0.0001cNeedling9.25±9.84(0.5, 5, 19.5)12.92±8.61(5.5, 13, 19.2)3.17±3.6(0.75, 2, 5.5)10.3±9.2(2, 8, 18)0.08cNotes: aMean ±SD (25% percentile, Median, 75% Percentile). bChi-square test. cOne-way ANOVA test. Table 3GPT and Needling ProceduresProceduresPhaco-NPDSNPDS-IOLNPDS-PhakicAllP-valueNumber of eyes(%)GPT106/132(80.3%)81/94(86.17%)13/19(68.42%)200/245(81.63%)0.16bNeedling25/146(17.12%)26/100(26%)6/30(20%)57/276(21%)0.82bMeana period from NPDS to procedure (Months)GPT13.38±17.2(1.1, 6.7, 19)7.2±11.72(1, 3, 7.9)14.26±25.43(2.2, 4, 10.1)10.94±16.12(1.1, 3.9, 12.5)0.11cNeedling5.76±9.45(1, 2, 6.6)7.78±9.92(1.8, 4.1, 9.2)5.2±5.56(1.5, 3.5, 7.9)6.65±9.27(1.2, 3.1, 7.3)0.59cMeana Delta IOP (mmHg)GPT7.93±5.67(5, 6, 10)12.88±8.6(7, 10, 18)9.4±5.17(5, 10, 13.5)10.02±7.4(5, 8, 13)<0.0001cNeedling9.25±9.84(0.5, 5, 19.5)12.92±8.61(5.5, 13, 19.2)3.17±3.6(0.75, 2, 5.5)10.3±9.2(2, 8, 18)0.08cNotes: aMean ±SD (25% percentile, Median, 75% Percentile). bChi-square test. cOne-way ANOVA test. GPT and Needling Procedures Notes: aMean ±SD (25% percentile, Median, 75% Percentile). bChi-square test. cOne-way ANOVA test. Needling Procedures Of the 276 eyes, 57 (21%) underwent Needling procedures following NPDS surgery (Table 3). There was no significant difference in the prevalence of Needling between the three groups (p=0.82). The odds ratio for Needling was higher in the NPDS-IOL group compared to the Phaco-NPDS and NPDS-Phakic groups (OR=1.7, 1, and 1.21, respectively). The mean interval between NPDS surgery and Needling procedure was 6.65±9.27 months. There was no significant difference in the mean interval periods between the groups (p=0.59). In each group, the mean IOP decreased significantly after Needling, except in the NPDS-Phakic group, which was nearly significant (Phaco-NPDS p<0.0001, NPDS-IOL p<0.0001, and NPDS-Phakic p=0.06). There was no significant difference in the mean delta IOP between the groups (p=0.08), with a trend that did not reach statistical significance. Surgical Success The qualified and complete surgical success rates of each group at 1, 3 and 5 years after surgery for various IOP upper limits, including ≤21 mmHg, ≤18 mmHg, ≤15 mmHg, and ≤12 mmHg, are presented in Table 4. There were no statistically significant differences among the three groups regarding the qualified and complete surgical success rates at 1, 3, and 5 years after surgery across all IOP ranges.Table 4Qualified and Complete Success at 1, 3 and 5 Years After Surgery According to Target IOP RangesIOP RangeTime (Years)Phaco-NPDSNPDS-IOLNPDS-PhakicP-value*Q%C%Q%C%Q%C%Q%aC%b5–21 mmHg187.6%84.24%91%84%93.34%86.67%0.540.94381.51%72.6%85%77%90%76.67%0.470.71578.1%69.18%80%70%86.67%76.67%0.560.725–18 mmHg185.62%82.2%90%83%93.34%86.67%0.370.84378.77%71.23%83%76%90%76.67%0.310.65576.02%67.81%77%69%86.67%76.67%0.440.635–15 mmHg179.4%76.02%82%76%93.34%86.67%0.370.84373.28%65.75%75%69%86.67%76.67%0.310.65569.2%60.9%70%64%83.34%73.34%0.290.435–12 mmHg154.79%53.42%63%61%76.67%73.34%0.060.1345.89%42.46%54%52%63.34%53.34%0.160.26541.78%38.35%50%48%53.34%50%0.310.23Notes: Q% - Qualified Success. C% - Complete Success. * Chi-Square Log-Rank (Mantel-Cox) test. Q%a - P-value of Q% Phaco-NPDS vs. Q% NPDS-IOL vs. Q% NPDS-Phakic. C%b - P-value of C% Phaco-NPDS vs. C% NPDS-IOL vs. C% NPDS-Phakic. Table 4Qualified and Complete Success at 1, 3 and 5 Years After Surgery According to Target IOP RangesIOP RangeTime (Years)Phaco-NPDSNPDS-IOLNPDS-PhakicP-value*Q%C%Q%C%Q%C%Q%aC%b5–21 mmHg187.6%84.24%91%84%93.34%86.67%0.540.94381.51%72.6%85%77%90%76.67%0.470.71578.1%69.18%80%70%86.67%76.67%0.560.725–18 mmHg185.62%82.2%90%83%93.34%86.67%0.370.84378.77%71.23%83%76%90%76.67%0.310.65576.02%67.81%77%69%86.67%76.67%0.440.635–15 mmHg179.4%76.02%82%76%93.34%86.67%0.370.84373.28%65.75%75%69%86.67%76.67%0.310.65569.2%60.9%70%64%83.34%73.34%0.290.435–12 mmHg154.79%53.42%63%61%76.67%73.34%0.060.1345.89%42.46%54%52%63.34%53.34%0.160.26541.78%38.35%50%48%53.34%50%0.310.23Notes: Q% - Qualified Success. C% - Complete Success. * Chi-Square Log-Rank (Mantel-Cox) test. Q%a - P-value of Q% Phaco-NPDS vs. Q% NPDS-IOL vs. Q% NPDS-Phakic. C%b - P-value of C% Phaco-NPDS vs. C% NPDS-IOL vs. C% NPDS-Phakic. Qualified and Complete Success at 1, 3 and 5 Years After Surgery According to Target IOP Ranges Notes: Q% - Qualified Success. C% - Complete Success. * Chi-Square Log-Rank (Mantel-Cox) test. Q%a - P-value of Q% Phaco-NPDS vs. Q% NPDS-IOL vs. Q% NPDS-Phakic. C%b - P-value of C% Phaco-NPDS vs. C% NPDS-IOL vs. C% NPDS-Phakic. Kaplan-Meier survival curves for qualified and complete surgical success by various IOP ranges are shown in Figure 4. Regarding the IOP target range of 5–21 mmHg, the qualified and complete success rates were 78.1% and 69.2% in the Phaco-NPDS group, 79% and 68% in the NPDS-IOL group, and 83.4% and 73.3% in the NPDS-Phakic group, respectively. The Log-rank (Mantel-Cox) test showed no statistically significant difference in qualified or complete surgical success among the three groups (p=0.46 and p=0.16, respectively). Regarding the IOP target range of 5–18 mmHg, the qualified and complete success rates were 76.02% and 67.81% in the Phaco-NPDS group, 76% and 67% in the NPDS-IOL group, and 83.3% and 73.3% in the NPDS-Phakic group, respectively. The Log-rank (Mantel-Cox) test showed no statistically significant difference in qualified or complete surgical success among the three groups (p=0.35 and p=0.13, respectively). Regarding the IOP target range of 5–15 mmHg, the qualified and complete success rates were 69.18% and 60.96% in the Phaco-NPDS group, 70% and 64% in the NPDS-IOL group, and 83.3% and 73.3% in the NPDS-Phakic group, respectively. The Log-rank (Mantel–Cox) test showed no statistically significant difference in qualified or complete surgical success among the three groups (p=0.17 and p=0.07, respectively), with the complete success comparison showing a trend that did not reach statistical significance. Regarding the IOP target range of 5–12 mmHg, the qualified and complete success rates were 41.78% and 38.36% in the Phaco-NPDS group, 50% and 48% in the NPDS-IOL group, and 53.3% and 50% in the NPDS-Phakic group, respectively. The Log-rank (Mantel-Cox) test revealed no statistically significant difference in qualified surgical success among the three groups (p=0.1); however, a statistically significant difference was observed in complete surgical success (p=0.034). Subgroup analysis demonstrated a statistically significant difference between the Phaco-NPDS and NPDS-Phakic groups (p=0.02), while no significant difference was found between the Phaco-NPDS and NPDS-IOL groups (p=0.07, suggesting a trend that did not reach statistical significance), nor between the NPDS-IOL and NPDS-Phakic groups (p=0.31). Figure 4Kaplan–Meier survival curves over time (years) showing qualified success (left panels) and complete success (right panels). Red lines represent the Phaco-NPDS group, blue lines represent the NPDS-IOL group, and green lines represent the NPDS-Phakic group. Numbers at risk are shown as Phaco-NPDS/NPDS-IOL/NPDS-Phakic at 0, 1, 3, and 5 years. Panels correspond to target IOP ranges: (A) 5–21 mmHg: 146/100/30, 109/78/29, 72/56/26, 44/34/17; (B) 5–18 mmHg: 146/100/30, 106/77/29, 69/54/26, 43/33/17; (C) 5–15 mmHg: 146/100/30, 100/69/29, 67/48/25, 42/31/16; (D) 5–12 mmHg: 146/100/30, 68/54/26, 41/35/19, 20/22/12.The image A shows Kaplan-Meier survival curves for the IOP range of 5 to 21 millimeters of mercury. The left graph shows qualified survival over time in years, with the y-axis labeled as Qualified Survival and the x-axis as Time (Years). The right graph shows complete survival with the same axes. The image B shows Kaplan-Meier survival curves for the IOP range of 5 to 18 millimeters of mercury. The left graph shows qualified survival and the right graph shows complete survival, both with the same axes as image A. The image C shows Kaplan-Meier survival curves for the IOP range of 5 to 15 millimeters of mercury. The left graph shows qualified survival and the right graph shows complete survival, both with the same axes as image A. The image D shows Kaplan-Meier survival curves for the IOP range of 5 to 12 millimeters of mercury. The left graph shows qualified survival and the right graph shows complete survival, both with the same axes as image A.Kaplan-Meier curves for IOP ranges: 5-21, 5-18, 5-15, 5-12 mmHg, showing success rates. Kaplan–Meier survival curves over time (years) showing qualified success (left panels) and complete success (right panels). Red lines represent the Phaco-NPDS group, blue lines represent the NPDS-IOL group, and green lines represent the NPDS-Phakic group. Numbers at risk are shown as Phaco-NPDS/NPDS-IOL/NPDS-Phakic at 0, 1, 3, and 5 years. Panels correspond to target IOP ranges: (A) 5–21 mmHg: 146/100/30, 109/78/29, 72/56/26, 44/34/17; (B) 5–18 mmHg: 146/100/30, 106/77/29, 69/54/26, 43/33/17; (C) 5–15 mmHg: 146/100/30, 100/69/29, 67/48/25, 42/31/16; (D) 5–12 mmHg: 146/100/30, 68/54/26, 41/35/19, 20/22/12. Cox proportional hazards regression models, with variables including gender, age, and diagnosis, were used to compare surgical success rates among the three groups. Regarding an IOP range of 21–5 mmHg, and in comparison to the Phaco-NPDS group: for qualified surgical success, the NPDS-IOL group showed no significant difference compared to the Phaco-NPDS group (p=0.696), with a hazard ratio (HR) of 0.9 (95% CI: 0.52–1.55). The NPDS-Phakic group showed no significant difference compared to the Phaco–NPDS group (p=0.219), with a hazard ratio (HR) of 0.55 (95% CI: 0.21–1.42). For complete surgical success, the NPDS-IOL group showed no significant difference compared to the Phaco-NPDS group (p=0.603), with a hazard ratio (HR) of 0.89 (95% CI: 0.56–1.4). The NPDS-Phakic group showed no significant difference compared to the Phaco–NPDS group (p=0.061), with a hazard ratio (HR) of 0.48 (95% CI: 0.22–1.03), suggesting a trend toward a lower hazard in the NPDS-Phakic group. No demographic or diagnostic covariates were associated with surgical outcomes. Regarding an IOP range of 18–5 mmHg, and in comparison to the Phaco-NPDS group: for qualified surgical success, the NPDS-IOL group showed no significant difference compared to the Phaco-NPDS group (p=0.804), with a hazard ratio (HR) of 0.94 (95% CI: 0.56–1.57). The NPDS-Phakic group showed no significant difference compared to the Phaco–NPDS group (p=0.157), with a hazard ratio (HR) of 0.51 (95% CI: 0.2–1.4). For complete surgical success, the NPDS-IOL group showed no significant difference compared to the Phaco-NPDS group (p=0.563), with a hazard ratio (HR) of 0.88 (95% CI: 0.56–1.37). The NPDS-Phakic group showed significant difference compared to the Phaco–NPDS group (p=0.049), with a hazard ratio (HR) of 0.46 (95% CI: 0.22–1). No demographic or diagnostic covariates were associated with surgical outcomes. Regarding an IOP range of 15–5 mmHg, and in comparison to the Phaco-NPDS group: for qualified surgical success, the NPDS-IOL group showed no significant difference compared to the Phaco-NPDS group (p=0.996), with a hazard ratio (HR) of 1 (95% CI: 0.64–1.57). The NPDS-Phakic group showed no significant difference compared to the Phaco–NPDS group (p=0.072), with a hazard ratio (HR) of 0.46 (95% CI: 0.19–1.07), suggesting a trend toward a lower hazard in the NPDS-Phakic group. For complete surgical success, the NPDS-IOL group showed no significant difference compared to the Phaco-NPDS group (p=0.728), with a hazard ratio (HR) of 0.93 (95% CI: 0.62–1.4). The NPDS-Phakic group showed significant difference compared to the Phaco–NPDS group (p=0.026), with a hazard ratio (HR) of 0.43 (95% CI: 0.2–0.9). No demographic or diagnostic covariates were associated with surgical outcomes. Regarding an IOP range of 12–5 mmHg, and in comparison to the Phaco-NPDS group: for qualified surgical success, the NPDS-IOL group showed no significant difference compared to the Phaco-NPDS group (p=0.108), with a hazard ratio (HR) of 0.75 (95% CI: 0.53–1.06). The NPDS-Phakic group showed no significant difference compared to the Phaco–NPDS group (p=0.068), with a hazard ratio (HR) of 0.6 (95% CI: 0.35–1.04), suggesting a trend toward a lower hazard in the NPDS-Phakic group. For complete surgical success, the NPDS-IOL group showed no significant difference compared to the Phaco-NPDS group (p=0.063), with a hazard ratio (HR) of 0.73 (95% CI: 0.52–1.02), suggesting a trend toward a lower hazard in the NPDS-IOL group. The NPDS-Phakic group showed significant difference compared to the Phaco–NPDS group (p=0.026), with a hazard ratio (HR) of 0.54 (95% CI: 0.32–0.93). No demographic or diagnostic covariates were associated with surgical outcomes. 17 out of 276 eyes (6.16%) underwent bleb revision surgery either due to under or over filtration. Of them, 35.3% were from Phaco-NPDS group, 47.1% were from NPDS-IOL group, and 17.65% were from NPDS-Phakic group. The proportion of eyes requiring bleb revision did not differ significantly among the groups (p=0.25). The mean period from NPDS surgery to bleb revision was 1.83±1.72 years. 6 out of 276 eyes (2.2%) underwent additional filtration surgery due to NPDS surgery failure. Of those, 50% were from Phaco-NPDS group, 33.3% were from NPDS-IOL group, and 16.7% were from NPDS-Phakic group. The proportion of eyes requiring filtration surgery did not differ significantly among the groups (p=0.7). The mean interval between primary NPDS and the additional filtration surgery was 4.84±2.85 years. Complications Incarceration of the iris in the opening of the TDM window after GPT procedure (post-GPT incarceration) occurred in 21 out of 200 eyes (10.5%) that underwent GPT procedure. There was no significant association between complications and surgery type (χ2=1.76, p=0.41). Incarcerations were treated successfully with different regimens combining topical pilocarpine, laser iridoplasty, or surgical release using a 30-gauge needle through a peripheral corneal entry into the anterior chamber (A/C Needling) in a sterile fashion. Hypotony causing persistent choroidal detachment, hypotony maculopathy, or a decrease in vision occurred in 8 out of 276 eyes (2.9%). Two eyes (0.72%) had blebitis and endophthalmitis; one eye (NPDS-IOL group) developed blebitis and endophthalmitis one month after Needling, and the other eye (Phaco-NPDS group) did so two years after bleb revision. Two eyes (0.72%) underwent eye removal surgery; one eye (NPDS-IOL group) was eviscerated due to a blind-painful eye after failure to treat persistent hypotony and hemorrhagic choroidal detachment, and the other eye (Phaco-NPDS group) was enucleated due to iris melanoma. Discussion In this cohort with long-term follow-up, combined Phaco-NPDS achieved outcomes comparable to standalone NPDS in terms of surgical success, IOP control, medication burden, and overall safety. These findings support the use of combined Phaco-NPDS in patients with coexisting cataract and glaucoma when clinically indicated, without an apparent compromise in NPDS efficacy. Differences in mean age and preoperative visual acuity among groups likely reflect clinical selection of surgical approach, with cataract surgery deferred in younger phakic patients with good visual acuity (NPDS-Phakic group), whereas older pseudophakic patients (NPDS-IOL group) had already undergone cataract surgery. On multivariable Cox proportional hazards regression models adjusted for age, sex, and diagnosis, there were no significant differences in qualified or complete surgical success between the Phaco-NPDS and NPDS-IOL groups across all IOP upper limits, suggesting that combining cataract surgery with NPDS did not adversely affect long-term success. The NPDS-Phakic group, which was the smallest and youngest subgroup, showed no significant differences in qualified success but demonstrated significantly better complete success at stricter IOP targets of ≤18, ≤15, and ≤12 mmHg compared with the Phaco-NPDS group. This may reflect differences in wound-healing responses and outflow tissue characteristics in younger phakic eyes, and the absence of cataract surgery before or during NPDS, as postoperative inflammation after cataract surgery may increase subconjunctival or bleb-related scarring and make it more difficult to achieve very low IOP targets. In addition, Phaco-NPDS may have been selected for older or more complex cases, which may be more likely to require IOP-lowering medications to achieve adequate disease control and stricter target IOPs, resulting in lower complete success rates. Our results are consistent with findings from the limited number of published studies comparing combined Phaco-NPDS to NPDS alone.22,27–29 D’Eliseo et al,27 in a one-year study, reported that NPDS combined with phacoemulsification (defined as IOP <20 mmHg without medication) had a higher success rate than NPDS alone (90% vs 62%). Wishart et al,28 in a three-year study, found no significant difference in success rates between Phaco-NPDS (94%) and NPDS alone (77%) Xiao et al,29 in their meta-analysis, reported that Phaco-NPGS resulted in greater postoperative IOP reduction and a more favorable safety profile than NPGS alone, concluding that Phaco-NPGS may be a preferable option for glaucoma patients with coexisting cataracts. In addition, at 2-year follow-up, Correia Barbosa et al30 reported comparable complete and qualified success rates between NPDS (50.83% and 60.83%) and trabeculectomy (51.85% and 65.43%), with no significant difference between groups, while noting a lower risk of complications with NPDS. The NPDS-Phakic group had a higher odds ratio for perforation than the other groups, which may reflect differences in ocular anatomy in phakic eyes. These eyes were younger in our cohort and may have less rigid tissue characteristics during deep scleral dissection, potentially making them more prone to perforation. Regarding postoperative procedures, GPT and Needling have an important role in post-NPDS glaucoma management.31,32 Both were more frequently performed during the first postoperative year and were used more often in the NPDS-IOL group. This pattern may reflect differences in tissue characteristics in eyes that had undergone cataract surgery before NPDS, with a potentially higher tendency toward increased Trabeculo-Descemet membrane outflow resistance and/or subconjunctival bleb-related scarring due to postoperative inflammation after cataract surgery. Xiao et al,29 in their meta-analysis on NPGS surgery, reported that four studies examined the need for GPT or Needling after NPGS, though only one specifically investigated NPDS. Their analysis found that the Phaco-NPGS group had a significantly lower prevalence of postoperative procedures compared to the NPGS-alone group (p<0.00001). Penaud et al31 found that most eyes undergoing NPDS surgery required GPT to lower IOP below the target pressure, with the majority of GPT procedures (77.6%) performed within the first postoperative year, consistent with our findings. Rates of bleb revision surgery were low overall, occurring in 17 out of 276 eyes (6.16%) at a mean interval of 1.9±1.8 years after NPDS, and did not differ significantly among groups (p=0.25), supporting comparable long-term safety profiles with respect to clinically significant under or over filtration requiring revision. Additionally, further filtration surgery for NPDS failure was infrequent, required in 6 out of 276 eyes (2.2%) at a mean interval of 4.11±2.7 years postoperatively, and did not differ significantly among groups (p=0.7), suggesting that the small proportion of failures requiring additional glaucoma surgery tended to occur later during follow-up. Wishart et al28 reported that 2 out of 76 eyes (2.63%) required additional glaucoma surgery after standalone NPDS. Jampel et al33 noted that surgery for bleb-related complications was performed in 8.8% of eyes following trabeculectomy. In terms of complications, the most common in our study was iris incarceration in the opening of the TDM window after a GPT procedure (post-GPT incarceration), occurring in 21 out of 200 eyes (10.5%). There was no significant association between iris incarceration and surgery type (p=0.41). All cases were successfully managed without serious consequences. Similarly, Penaud et al31 found that iris incarceration after GPT was the most frequent complication, occurring in 22 out of 125 eyes (17.6%). D’Eliseo et al27 reported that complications were generally uncommon but occurred more frequently in the NPDS-alone group than in the Phaco-NPDS group, including hypotony (32.2% vs. 20%), hyphema (3.2% vs. 0%), and iris prolapse (3.2% vs. 0%). Cillino et al34 observed that hyphema was more common (17.6% vs. 13.3%), followed by early hypertension (11.8% vs. 13.3%), inflammation (5.9% vs. 0%), and a shallow anterior chamber (5.9% vs. 0%). Limitations of this study include its retrospective design, the smaller sample size of the NPDS-Phakic group compared with the other two groups, and variability in follow-up duration. In addition, the recorded visual acuities were not best-corrected values and may therefore underestimate true visual acuity. Finally, the inconsistent availability of structural and functional glaucoma progression measures (eg. OCT retinal nerve fiber layer/ganglion cell analysis and standardized visual field progression) limited the analysis of these endpoints. Conclusions Combining phacoemulsification with NPDS was not associated with reduced surgical success and achieved comparable long-term IOP control, medication burden, and safety to standalone NPDS. GPT and needling were most frequently performed during the first postoperative year across all groups and remain important components of post-NPDS glaucoma management. Accordingly, Phaco-NPDS should be considered in patients with coexisting cataract and open-angle glaucoma when surgical intervention is clinically indicated. In younger phakic eyes without cataract, standalone NPDS may be considered to achieve higher complete success rates at stricter IOP targets. Therefore, surgical decision-making should be individualized, considering lens status, cataract burden, age, and glaucoma characteristics. Future prospective studies with standardized follow-up intervals and incorporation of functional and structural glaucoma progression measures are needed to better define long-term comparative effectiveness and optimize patient selection for combined versus standalone NPDS.